Ramipril is a widely prescribed angiotensin-converting enzyme (ACE) inhibitor used in the treatment of hypertension, kidney disease, and heart failure. The error occurred during the secondary packaging process for Batch GR155023. Since both batches were manufactured at the same site, the MHRA determined that the issue was isolated to the packaging stage rather than the production of the capsules themselves. The recall notice advises healthcare professionals to stop supplying the impacted batch immediately and to return affected stock to their suppliers. For pharmacists, the directive is clear: if traceability information is available, they must contact patients to verify the medicines dispensed. If traceability is unavailable, pharmacists are instructed to identify all patients who received the product between 16 January 2026 and 22 May 2026, prioritizing those dispensed within the last 28 days.
The medical significance of this error lies in the pharmacological profile of ramipril. While a limited exposure to a higher dose is unlikely to result in serious harm for the majority of patients, the risk is not zero. Paul Wright, a consultant cardiovascular pharmacist at Barts Heart Centre, Barts Health NHS Trust, noted that the recall is critical “given the potential for a four-fold increase in dose.” He explained that clinically relevant effects may include feeling lightheaded, fainting, experiencing fatigue, or suffering from altered kidney function. These symptoms can be more serious for vulnerable patients, potentially requiring additional investigation. As a large cardiac centre, Barts Health is contacting a large volume of patients as part of this recall effort, illustrating the scale of coordination required when a common medication is affected by a supply chain error.
Alison Cave, chief safety officer at the MHRA, provided specific guidance for patients to check their own medication. She advised individuals taking Crescent Pharma Limited ramipril 2.5mg capsules to examine the outer carton for the batch number GR155023. If this batch number is present, patients should verify that the strength on the carton matches the blister strips inside. If a 2.5mg carton contains blister strips labelled as ramipril 10mg capsules, patients must not take the medicine and should contact their dispensing pharmacy. Conversely, if the blister strips are correctly labelled as 2.5mg, no further action is needed, and patients should continue taking their medicine as usual.
The distinction between the medication itself and the packaging error is crucial for understanding the risk. The MHRA emphasized that if a patient believes they have taken 10mg capsules in error and are experiencing side effects, they should seek medical advice. The agency specified that signs and symptoms may include lightheadedness, fainting, fatigue, or altered kidney function. Any possible impact of taking a higher dose of ramipril should be assessed by a healthcare professional to determine whether any examination or tests are needed. This approach balances the need for vigilance with the understanding that a single instance of accidental over-dosage is rarely catastrophic, but still warrants professional evaluation to prevent complications, particularly in patients with pre-existing kidney disease or those on other blood pressure-lowering medications.
The response to this recall highlights the robustness of the UK’s medication safety systems. By issuing a Class 2 recall, the MHRA classified the error as one that could temporarily affect health but is unlikely to cause serious adverse health consequences. The swift publication of the notice on the same day the manufacturer, Crescent Pharma, confirmed the recall demonstrates the close liaison between industry and regulatory bodies. For healthcare professionals, the immediate cessation of supply and the initiation of patient contact protocols serve as a safeguard against further distribution of the mixed packs. The focus remains on traceability, ensuring that every patient who may have received the incorrect strength is identified and informed.
While the sources confirm the specific details of the recall and the official guidance, they do not provide data on the total number of patients affected or the exact extent of the distribution beyond the specified date range. However, the involvement of major institutions like Barts Health NHS Trust suggests a significant patient base is being engaged. The situation serves as a reminder of the importance of accurate packaging in pharmaceutical manufacturing, where a simple mix-up can lead to widespread clinical concern. As of 28 May 2026, the next confirmed development is the ongoing process of healthcare professionals contacting patients and the return of affected stock to suppliers, with the MHRA monitoring the situation to ensure the recall is effective.
